Wang Zhu, Zhao He, Wang Xiaoze, Zhang Hailong, Jiang Mingshan, Tsauo Jiaywei, Luo Xuefeng, Yang Li, Li Xiao
Institution of Intervention Radiology, West China Hospital, Sichuan University, 37# Guoxue Lane, Chengdu, 610041, Sichuan, China.
Abdom Imaging. 2015 Aug;40(6):1813-20. doi: 10.1007/s00261-014-0320-9.
The aim of this study is to compare the clinical outcomes of transjugular intrahepatic portosystemic shunt (TIPS) and endoscopic band ligation (EBL) in patients with cirrhosis and portal vein thrombosis (PVT). We retrospectively reviewed the January to September 2010 data from our database and included 25 patients with cirrhosis and PVT who underwent successful TIPS creation. We selected another 25 patients who underwent EBL matching for age, sex, and Child-Pugh-Turcotte class. The outcome measures included changes in the PVT status before and after the treatments, the rebleeding rate, and the overall survival. The mean follow-up was 25.1 ± 8.7 months in the EBL group and 25.6 ± 8.5 months in the TIPS group (P = 0.85). After treatments, the PVT severity improved in 40% and worsened in 25% of patients who did not undergo TIPS, compared with 87% and none of the patients who underwent TIPS (P < 0.001). Previous splenectomy (OR 0.13, 95% CI 0.02-0.76, P = 0.024) and patency status of TIPS (OR 20.8, 95% CI 3.0-141.8, P = 0.002) were the independent factors associated with PVT disappearance. The 1- and 2-year rebleeding rates were, respectively, 44.6% and 59.0% in the EBL group, and 12.5% and 25.2% in the TIPS group (P = 0.002). The 1- and 2-year survival rates were, respectively, 95.7% and 85.2% in the EBL group, and 96% and 78.7% in the TIPS group (P = 0.203). The MELD score was the only independent predictive factor for survival (HR 1.73, 95% CI 1.27-2.37, P = 0.001). Compared with EBL, TIPS contributed to PVT improvement and reduced the risk of rebleeding without providing a survival benefit for patients with PVT.
本研究旨在比较经颈静脉肝内门体分流术(TIPS)与内镜下套扎术(EBL)治疗肝硬化合并门静脉血栓形成(PVT)患者的临床疗效。我们回顾性分析了2010年1月至9月数据库中的数据,纳入了25例行TIPS成功建立的肝硬化合并PVT患者。我们另外选取了25例行EBL的患者,在年龄、性别和Child-Pugh-Turcotte分级方面进行匹配。观察指标包括治疗前后PVT状态的变化、再出血率和总生存率。EBL组的平均随访时间为25.1±8.7个月,TIPS组为25.6±8.5个月(P = 0.85)。治疗后,未行TIPS的患者中40%的PVT严重程度改善,25%恶化,而行TIPS的患者中分别为87%和0%(P < 0.001)。既往脾切除术(比值比0.13,95%置信区间0.02 - 0.76,P = 0.024)和TIPS通畅状态(比值比20.8,95%置信区间3.——141.8,P = 0.002)是与PVT消失相关的独立因素。EBL组1年和2年再出血率分别为44.6%和59.0%,TIPS组分别为12.5%和25.2%(P = 0.002)。EBL组1年和2年生存率分别为95.7%和85.2%,TIPS组分别为96%和78.7%(P = 0.203)。终末期肝病模型(MELD)评分是生存的唯一独立预测因素(风险比1.73,95%置信区间1.27 - 2.37,P = 0.001)。与EBL相比,TIPS有助于改善PVT并降低再出血风险,但对PVT患者未提供生存获益。